
No Stock Yet
Loading...
No Stock Yet
No Data
Editas Medicine's Return On Capital Employed Insights
Benzinga Pro data, Editas Medicine (NASDAQ:EDIT) reported Q1 sales of $6.77 million. Earnings fell to a loss of $50.52 million, resulting in a 21.91% decrease from last quarter. In Q4, Editas Medicin
Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting
SLEEK results in highly efficient multi-transgene knock-in and enables tunability of transgene expression Double knock-in iNK cells demonstrate strong tumor killing effect and prolonged in vivo persis
Why Editas Medicine's Shares Fell 28.9% This Week
The company's progress for its lead therapy has been slow. What happened Shares of Editas Medicine (EDIT 9.34%), a genome editing biotech company that uses CRISPR/Cas9 and CRISPR/Cas12a genome editi
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia
The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.
Editas Medicine Gets FDA Orphan Drug Designation for Blood Disorder Candidate
04:31 AM EDT, 05/13/2022 (MT Newswires) -- Editas Medicine (EDIT) said late Thursday the US Food and Drug Administration has granted orphan drug designation to EDIT-301 for the potential treatment of
Editas Medicine granted Orphan Drug Designation for beta thalassemia candidate
The U.S. FDA has granted Orphan Drug designation to Editas Medicine (NASDAQ:EDIT) for EDIT-301, its candidate for beta thalassemia. The company is planning to dose the first person in a phase 1/2 tria
Editas Medicine Shares Tick Down 1.5% on EDIT-301 FDA Designation
By Denny Jacob Editas Medicine Inc. shares fell 1.5% to $10.65 in after-hours trading Thursday after it said the Food and Drug Administration granted EDIT-301 orphan drug designation. EDIT
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to EDIT-301, an investigational,
Morgan Stanley Lowers Editas Medicine's Price Target to $15 From $17, Underweight Rating Kept
12:45 PM EDT, 05/09/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Expert Ratings for Editas Medicine
Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 1 2 0 Last 30D 0 0 0